Stock Analysis of Aytu BioScience Inc (AYTU) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code AYTU
Close 2.94
Change -0.0200 / 0.676 %
Volume 21134.00
Vol Change -19523.00 / 48.02 %
IndustryDrug Manufacturers-Specialty & Generic
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Excellent Growth
Value Index Mild Value
Profitability Index Poor Profitability Stock
Stability Index Very Low Stability Stock


Fundamental View of Aytu BioScience Inc


Highs/Lows of Aytu BioScience Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week3.27 10.09 % 1.54 % 3.44752.7514-May-2416-May-24
Two Week3.01 2.33 % 3.42 % 3.44752.7514-May-2416-May-24
One Month2.8733 2.32 % 5.60 % 3.44752.6314-May-2424-Apr-24
Three Month3.17 7.26 % 5.95 % 3.44752.6314-May-2424-Apr-24
Six Months2.29 28.38 % 17.48 % 3.452.2215-Feb-2411-Dec-23
One year1.81 62.43 % 27.52 % 3.51.3818-Oct-2329-Jun-23
Two year10.988 73.24 % 29.70 % 4.881.3821-Dec-2229-Jun-23
Five year380.0 99.23 % 85.46 % 5.691.3825-Aug-2229-Jun-23


Technical View of Aytu BioScience Inc






Charts of Aytu BioScience Inc


Returns of Aytu BioScience Inc with Peers
Period / StockAYTUKALAFLGCACRXCEMI
1 Week-10.09%-5.07%-4.38%16.47%1.11%
1 Mth2.32%-4.21%-26.82%21.37%30.00%
3 Mth-7.26%-7.62%39.79%31.45%30.00%
6mth28.38%20.18%42.89%-26.68%37.88%
1 Year62.43%-64.84%-71.52%-60.59%-26.61%
2 Year-73.24%-82.29%-95.00%-92.12%-88.60%
5 Years-99.23%-97.80%--98.29%-94.31%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Aytu BioScience Inc with Peers
Ratio / StockAYTUKALAFLGCACRXCEMI
PE-1.90-99.19-0.193-755768.51-0.341
P/B0.415295.690.6123520391.28
ROA-5.90-64.03-146.99-26.23-77.29
ROE-21.88-298.09-309.38-46.58-167.79
Debt To Equity0.4164.600.42601.10
Revenue107399 K
11.10 %
0
100.00 %
72416.00 K
94.82 %
2141.00 K
20.89 %
49522.00 K
3.56 %
Net Income-17051.00 K
84.52 %
-46415.00 K
3.55 %
-59766.00 K
13.56 %
-21364.00 K
144.74 %
-23290.00 K
31.31 %


Technicals of Aytu BioScience Inc with Peers
Technical / StockAYTUKALAFLGCACRXCEMI-
ADX19.4222.6415.6432.3315.67
CMF-0.077-0.1100.126-0.2080.867
MFI56.9647.4872.5348.5645.40
RSI45.3240.4340.2667.0157.51
MACD Abv SignalFalseTrueFalseTrueFalse
Price Above 50 MAFalseFalseFalseTrueTrue-
Price Above 200 MATrueFalseFalseTrueTrue-


About : Aytu BioScience Inc


Address : Denver Corporate Center III, Denver, CO, United States, 80237
Tel : 720 437 6580
URL : https://aytubio.com
Code : AYTU, ISIN : US0547548745, Exchange : NASDAQ, Country : USA
Fiscal Year End : June
IPO date : 01_Feb_2017
Employee Count : 150

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.


Note : All Data Generated at the End of Trading Hours (EOD Data)